Drug Interactions between rifapentine and zaleplon
This report displays the potential drug interactions for the following 2 drugs:
- rifapentine
- zaleplon
Interactions between your drugs
rifapentine zaleplon
Applies to: rifapentine and zaleplon
GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of zaleplon. According to the prescribing information, CYP450 3A4 is a minor metabolizing enzyme of zaleplon. When zaleplon was coadministered with the potent CYP450 3A4 inducer rifampin (600 mg daily for 14 days), zaleplon plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately 80%. Reduced efficacy of zaleplon may occur.
MANAGEMENT: The use of zaleplon with potent CYP450 3A4 inducers should generally be avoided. An alternative sedative hypnotic agent that is not a CYP450 3A4 substrate may be considered in patients taking CYP450 3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
References (1)
- (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
Drug and food interactions
rifapentine food
Applies to: rifapentine
ADJUST DOSING INTERVAL: Administration with food may increase the oral bioavailability of rifapentine and reduce the incidence of gastrointestinal adverse events. Administration with a high fat meal typically increases rifapentine's maximum concentration (Cmax) and systemic exposure (AUC) by approximately 40% to 50% over that observed when rifapentine is administered under fasting conditions. Rifapentine is often prescribed in combination with isoniazid. When single doses of rifapentine (900 mg) and isoniazid (900 mg) were administered with a low fat, high carbohydrate breakfast, the Cmax and AUC of rifapentine increased by 47% and 51%, respectively. On the other hand, isoniazid's Cmax and AUC decreased by 46% and 23%, respectively.
MANAGEMENT: Products containing oral rifapentine as the sole ingredient recommend administration with a meal to increase bioavailability and reduce the occurrence of gastrointestinal upset, nausea, and/or vomiting. Consultation of product labeling for combination products and/or relevant guidelines may be helpful if rifapentine is combined with a medication that is typically taken on an empty stomach.
References (2)
- (2021) "Product Information. Isoniazid/Rifapentine 300 mg/300 mg (Macleods) (isoniazid-rifapentine)." Imported (India), 2
- (2021) "Product Information. Priftin (rifapentine)." sanofi-aventis
zaleplon food
Applies to: zaleplon
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of zaleplon. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
ADJUST DOSING INTERVAL: Administration of zaleplon with a high-fat or heavy meal may delay the onset of hypnotic effects. In healthy adult subjects, administration of zaleplon with a high-fat meal resulted in a 2-hour delay in the time to reach peak plasma drug concentration (Tmax) and a 35% reduction in the peak plasma drug concentration (Cmax) compared to fasting. Zaleplon systemic exposure (AUC) and elimination half-life were not significantly affected.
MANAGEMENT: Patients receiving zaleplon should be advised to avoid the consumption of alcohol. For faster sleep onset, zaleplon should not be administered with or immediately after a high-fat or heavy meal.
References (1)
- (2001) "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.